Adjuvant radiotherapy in carcinomas of the uterine cervix: the prognostic value of hemoglobin levels

Anemia has been associated with a poorer treatment response and reduced survival in women undergoing primary radiotherapy (RT) or radiochemotherapy for advanced cervical carcinoma. This study aimed to determine the influence of anemia on outcome in patients with cervical carcinoma undergoing adjuvant RT. Medical records were reviewed for 183 cervical cancer patients who had received adjuvant RT because of risk factors after radical surgery (n= 109) or inadequate primary surgery (simple hysterectomy; n= 74). Kaplan-Meier and Cox regression analyses were used to study hemoglobin levels before and during adjuvant RT in relation to recurrence-free and overall survival. Hemoglobin values > or =11 g/dL were considered normal, while those <11 g/dL indicated anemia. Hemoglobin levels before RT influenced significantly overall survival and recurrence-free survival across the whole group (overall survival--log rank(all patients)= 7.5; df = 1; P= 0.006). However, subgroup analysis showed that the observed difference was mainly due to the group of women who had undergone inadequate primary surgery (overall survival--log rank(inadequate surgery)= 10.8; df = 1; P= 0.001). Multifactorial regression analyses comparing hemoglobin before RT with grading and tumor stage confirmed the prognostic value of hemoglobin values. Maintaining normal hemoglobin values before and during adjuvant RT seems to be important, especially in patients who have had inappropriate simple hysterectomy, which may resemble a therapeutic situation.     

Gated myocardial perfusion single photon emission computed tomography in the clinical outcomes utilizing revascularization and aggressive drug evaluation (COURAGE) trial, Veterans Administration Cooperative study no. 424

Background  Stress gated myocardial perfusion single photon emission computed tomography (gSPECT) is increasingly used before and after intercurrent therapeutic intervention and is the basis for ongoing evaluation in the Department of Veterans Affairs clinical outcomes utilizing revascularization and aggressive drug evaluation (COURAGE) trial. Methods and Results  The COURAGE trial is a North American multicenter randomized clinical trial that enrolled 2287 patients to aggressive medical therapy vs percutaneous coronary intervention plus aggressive medical therapy. Three COURAGE nuclear substudies have been designed. The goals of substudy 0 are to examine the diagnostic accuracy of the extent and severity of inducible ischemia at baseline in COURAGE patients compared with patient symptoms and quantitative coronary angiography and to explore the relationship between inducible ischemia and the benefit from revascularization when added to medical therapy. Substudy 1 will correlate the extent and severity of provocative ischemia with the frequency, quality, and instability of recurrent symptoms in postcatheterization patients. Substudy 2 (n _ 300) will examine the usefulness of sequential gSPECT monitoring 6 to 18 months after therapeutic intervention. Together, these nuclear substudies will evaluate the role of gSPECT to determine the effectiveness of aggressive risk-factor modifications, lifestyle interventions, and anti-ischemic medical therapies with or without revascularization in reducing patients’ ischemic burdens. Conclusions  The unfolding of evidence on the application of gSPECT in trials such as COURAGE defines a new era for nuclear cardiology. We hope the evidence that emerges from the COURAGE trial will further establish the role of nuclear imaging in the evidence-based management of patients with stable coronary disease. The COURAGE trial was supported by the Cooperative Studies Program of the Department of Veterans Affairs Office of Research and Development in collaboration with the Canadian Institutes of Health Research. Unrestricted research grants were obtained from Merck & Co; Pfizer Pharmaceuticals; Bristol-Myers Squibb Medical Imaging; Astellas Pharma; Kos Pharmaceuticals; Data Scope; Astra Zeneca Pharmaceuticals; Astra-Zeneca-Canada; Schering-Plough Coorporation, Ltd; Sanofi-Aventis, Inc; First Horizon; and GE Healthcare. All industrial funding for this trial was directed through the Department of Veterans Affairs. Additional funding for this substudy was provided by grants to the Department of Veterans Affairs and Canadian Institutes of Health Research from Astellas Pharma and Bristol-Myers-Squibb Medical Imaging.     

p53,p16,PCNA蛋白在食管癌中的表达及其临床意义

目的探讨p53,p16,PCNA蛋白在食管癌中的表达及临床意义。方法用免疫组织化学染色SP法对62例食管癌标本进行p53,p16,PCNA蛋白测定。结果62例食管癌中,p53,PCNA蛋白阳性表达均为71.0%(44/62),p16缺失率48.4%(30/62)。p16缺失与肿瘤浸润深度、淋巴结转移密切相关(P<0.05、P<0.01)。而p53,PCNA蛋白同时表达56.5%(35/62),亦与肿瘤浸润深度、淋巴结转移密切相关(P<0.05、P<0.01)。结论食管癌p53,PCNA蛋白同时表达及p16缺失可视为危险预后因素。     

幕上星形细胞肿瘤Ki-67抗原表达及其预后作用

目的 探讨Ki-67抗原在幕上星形细胞肿瘤中的表达及其预后作用。方法 使用S-P免疫组化方法检测82例原发性幕上星形细胞肿瘤标本中Ki-67抗原的表达。单因素使用Kaplan-Meier法,多因素分析使用COX比例风险模型进行预后分析。结果Ki-67 指数在组织学分级GradeⅡ、Ⅲ、Ⅳ中分别为2.86%±1.57%,6.72%±3.95%,8.16%±3.92%(P<0.01)。单因素及多因素分析均提示Ki-67指数是独立的预后因素。在GradeⅡ中,Ki-67指数>2.5%与Grade Ⅲ中Ki-67指数≤2.5%的患者生存期差异无显著性(P>0.05);在GradeⅣ中,Ki-67指数≤2.5%与>2.5%的患者生存期有显著性差异(P<0.01)。结论 Ki-67指数随着各病理级别增高而增高;Ki-67指数>2.5%提示预后较差。在同一病理级别中,Ki-67指数不同,其预后有显著性差异。而部分不同病理级别的患者,随着Ki-67指数的不同,其生存期却无显著差异。联合组织病理检查及Ki-67指数检测有助于更精确地判断预后。     

高氧液对心肺脑复苏的作用

目的探讨高氧液静脉给药对肺心病患者心肺脑复苏成功率及预后的作用;方法采用高氧液静脉给药对26例心跳呼吸停止进行心肺脑复苏治疗的患者(观察组),与既往无高氧液静脉给药的35例心跳呼吸停止进行心肺脑复苏治疗的患者(对照组)进行复苏成功率及预后比较;结果观察组Ⅲ级和Ⅳ级复苏成功后生存11例,正常生活自理5例;对照组Ⅲ级和Ⅳ级复苏成功后生存4例,正常生活自理2例。两组Ⅲ级和Ⅳ级复苏成功率比较,观察组成功率较对照组高(P<0.01)。结论高氧液能提高心跳呼吸停止患者的心肺脑复苏成功率,可提高Ⅲ、Ⅳ级复苏的生存率。     

36例原发胃肠道淋巴瘤的诊断和治疗

目的：探讨提高原发胃肠道淋巴瘤术前诊断率及治疗效果的方法。方法：对36例原发胃肠道淋巴瘤患者的临床表现、体征及辅助检查进行分析，通过COX回归等统计方法对其预后因素及生存率等进行分析。结果：该病临床表现无特异性；诊断主要依靠内窥镜病理活检；手术方式、综合治疗完成情况、临床分期为与预后有关的影响因素。结论：提高对该病临床表现及内镜、造影检查特点的认识，采用正确的活检方法是提高术前诊断率的关键；以手术及化疗为主的综合治疗措施是提高疗效的关键。     

早期脑室置管行颅内压监护对中型颅脑损伤患者的预后影响

目的　探讨早期脑室置管行颅内压 (ICP)和脑灌注压 (CPP)监护在中型颅脑损伤中的临床应用价值。方法　将 12 5例伤后 2 4h入院无手术指征的中型颅脑损伤 (GCS 9～ 12分 )患者 ,随机分为ICP监护组 :入院后即经恻脑室内穿刺置管行ICP与CPP连续监测 ,根据颅内压变化调整治疗方案 ;对照组 :入院后不做ICP监测 ,依据临床观察的意识及生命体征变化 ,进行治疗。结果　颅内压监护组脱水剂剂量、应用时间均低于对照组 ,疗效优于对照组 ,两组差异有显著意义 (P <0 0 5 )。结论　中型颅脑损伤病情极不稳定 ,早期行ICP监护能及早发现病情变化 ,对及时采取有效治疗措施 ,降低死残率 ,改善预后有重要意义。     

128例双胎妊娠临床结局分析

目的 :探讨影响双胎妊娠临床结局的相关因素。方法 :回顾性分析 12 8例双胎妊娠临床结局与胎方位、分娩方式、孕周、新生儿体重、新生儿窒息之间的关系。 结果 :胎方位、孕周、胎儿体重及分娩方式均影响围产儿预后。 结论 :加强孕产期保健 ,提高产科质量能改善双胎妊娠围产儿的预后。